Loading insider details...
Beta
Latest Form 4 (Sep 2, 2026): Purchase of 2,098 ANTX shares, $11.6K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | AN2 Therapeutics, Inc. (ANTX) | Purchase | 2,098 | $11.6K |
| Mar 23, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 11,463 | n/a |
| Feb 23, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 20,400 | n/a |
| Sep 11, 2025 | Vistagen Therapeutics, Inc. (VTGN) | Grant/Award | 17,600 | n/a |
| May 29, 2025 | AN2 Therapeutics, Inc. (ANTX) | Purchase | 8,610 | $10.1K |
| May 23, 2025 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 19,111 | n/a |
| Sep 10, 2024 | Vistagen Therapeutics, Inc. (VTGN) | Grant/Award | 14,100 | n/a |
| Jun 21, 2024 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 64,503 | n/a |
| Mar 6, 2024 | Vistagen Therapeutics, Inc. (VTGN) | Grant/Award | 12,500 | n/a |
| Jun 10, 2023 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 23,742 | n/a |